Nuclear receptor coactivator: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
Line 6: | Line 6: | ||
*'''NCOA3''' shows histone acetyltransferase activity.<br /> | *'''NCOA3''' shows histone acetyltransferase activity.<br /> | ||
*'''NCOA5''' is both a DNA transcription coactivator and corepressor. It interacts with steroid receptor.<br /> | *'''NCOA5''' is both a DNA transcription coactivator and corepressor. It interacts with steroid receptor.<br /> | ||
*'''NCOA7''' may be a driver for beast cancer metastasis<ref>PMID:38699661</ref><br /> | |||
See also: [[Glucocorticoids]] and [[Steroid Hormones and their receptors]].<br />. | See also: [[Glucocorticoids]] and [[Steroid Hormones and their receptors]].<br />. | ||
== Structural highlights == | == Structural highlights == |
Latest revision as of 12:31, 17 July 2024
Nuclear receptor coactivator (NCOA) is a protein recruited by nuclear receptors in order to enhance or repress DNA transcription. NCOA is involved in coactivation with transcription factors[1].
See also: Glucocorticoids and Steroid Hormones and their receptors. Structural highlights
|
|
3D structures of nuclear receptor coactivator3D structures of nuclear receptor coactivator
Updated on 17-July-2024
2c52 – hNCOA1 residues 920-970 + CREB-binding protein – human
1kbh, 6es7, 6sqc – hNCOA3 1040-1086 + CREB-binding protein – NMR
1v95 – hNCOA5 anticodon binding domain 197-313 – human – NMR
8arp – hNCOA7 781-942
1oj5 – mNCOA1A Pas-B domain 257-367 + signal transducer and activator of transcription peptide – mouse
5y7w - mNCOA1A Pas-B domain + YL-2 peptide
ReferencesReferences
- ↑ Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol. 1996 Oct;10(10):1167-77. PMID:9121485 doi:http://dx.doi.org/10.1210/mend.10.10.9121485
- ↑ Peng Z, Li Y, Xia S, Dai Q, Yin L, Chen M, Yang W, Shao G, Lin Q. Expression of nuclear receptor co‑activator 7 protein is associated with poor prognosis of breast cancer. Oncol Lett. 2024 Apr 23;27(6):278. PMID:38699661 doi:10.3892/ol.2024.14411